Clavis Pharma

Companies Clavis Pharma

News Clavis Pharma

• Elacytarabine in combination with idarubicin shows promising efficacy in Phase II trial in acute myeloid leukaemia

  Clavis Pharma ASA announces data from its Phase II clinical trial with elacytarabine in combination with idarubicin. The trial enrolled patients with early stage acute myeloid leukaemia (AML), for whom cytarabine-containing first-course chemotherapy has failed.  The results found that treatment with more

• Clavis Pharma completes patient recruitment in Phase III study with elacytarabine in patients with acute myeloid leukaemia

  Clavis Pharma ASA announced that is has reached the enrolment target for its Phase III CLAVELA study investigating elacytarabine in patients with relapsed or refractory acute myeloid leukaemia (AML). Elacytarabine is a novel, patented lipid-conjugated form of the anti-cancer drug cytarabine, which i more

• Clavis Pharma announces negative outcome of pivotal LEAP Trial with CP-4126 in Patients with Metastatic Pancreatic Cancer

  Clavis Pharma ASA announced results of the LEAP (Low hENT1 and Adenocarcinoma of the Pancreas) study of CP-4126 (also known as CO-101), versus gemcitabine in metastatic pancreatic cancer. The trial, which was conducted by partner Clovis Oncology, Inc., showed that there was no difference in overall more

Market studies Clavis Pharma

• Clavis Pharma ASA (CLAVIS) - Financial and Strategic SWOT Analysis Review

  Clavis Pharma ASA (Clavis) is a publicly held clinical stage pharmaceutical company, engaged in the discovery and development of innovative small molecule therapies for the treatment of cancer. The products of Clavis are based on its proprietary Lipid Vector Technology (LVT) platform used in creatin more

• Nattopharma ASA (NATTO) - Financial and Strategic SWOT Analysis Review

  Nattopharma ASA (Nattopharma) is a publicly held company focusing primarily on research, developing and selling of vitamin K2. Its products are marketed under the trademark MenaQ7, the natural vitamin K2 derived from natto. MenaQ7 is available in two forms mainly powder and oil solution. It is empl more

• Clavis Pharma ASA – Product Pipeline Review – Q1 2011

  Introduction Global Market Direct’s pharmaceuticals report, “Clavis Pharma ASA - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discont more

Websites Clavis Pharma